Krishna Institute of Medical Sciences Limited (KIMS), a leading healthcare provider, has announced its unaudited financial results for the third quarter and nine months ended December 31, 2024. The Board of Directors, in a meeting held on February 6, 2025, approved the financial statements, which reflect the institution’s continued growth and stability despite challenges in the healthcare sector.
Financial Highlights
- Total Income for Q3 FY24-25: ₹34.75 crore
- An increase compared to ₹33.69 crore in the same period last year.
- Total Income for Nine Months (FY24-25): ₹107.07 crore
- Marking steady growth compared to the same period last year.
- Other Income for Q3: ₹2.0 crore
- Pushing the total income for the quarter to ₹34.95 crore.
- Operating Expenses for Q3: ₹26.62 crore
- An increase from ₹27.08 crore in Q3 FY23-24, due to rising medical consumables and employee benefits.
- Profit Before Tax (PBT) for Q3: ₹9.91 crore
- A significant rise from ₹8.36 crore last year.
- Profit After Tax (PAT) for Q3: ₹7.62 crore
- Showing strong financial performance despite increased costs.
- Profit After Tax (PAT) for Nine Months (FY24-25): ₹25.07 crore
- Further solidifying KIMS’s position in the healthcare sector.
- Comprehensive Income for Q3: ₹7.07 crore
- Driven by profit growth and other income.
- Earnings Per Share (EPS) for Q3: ₹1.91
- Reflecting positive performance and investor confidence.
Strategic Developments
- Acquisition of Chalasani Hospitals (Queens NRI Hospital):
- KIMS acquired 100% of Chalasani Hospitals for ₹14.12 crore.
- This acquisition strengthens KIMS’s position in the regional healthcare market, with the hospital now fully integrated as a subsidiary.
Future Outlook
- KIMS continues to expand through strategic acquisitions and the establishment of new hospitals, focusing on growth and operational efficiency.
- With a robust business model and experienced management, the company remains well-positioned for future success in the healthcare sector.
Krishna Institute of Medical Sciences Limited’s strong performance in Q3 FY24-25 demonstrates its continued success in providing high-quality healthcare services. With consistent revenue growth and strategic acquisitions, KIMS is set to thrive in the dynamic healthcare industry.
